ArticleCase reports in critical care2016
Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
Article in Case reports in critical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports.Journal of anesthesia · 2023Pooled it
- A novel corrected anion gap links metabolic acid attack to peptic ulcer disease.Frontiers in nutrition · 2026Article
- Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.International journal of molecular sciences · 2024Review
- Severe Prolonged SGLT2i-induced Euglycemic Diabetic Ketoacidosis Refractory to Standard Therapy and Dialysis: Case Report and Literature Review.Oman medical journal · 2022Article
- Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.The American journal of case reports · 2021Article
- Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature.Case reports in critical care · 2018Article
- Prolonged diabetic ketoacidosis associated with canagliflozin.Endocrinology, diabetes & metabolism case reports · 2018Article
- Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma.Endocrinology, diabetes & metabolism case reports · 2017Article
- Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Drug design, development and therapy · 2017Review
- The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.Oxford medical case reports · 2016Article
- Euglycemic Diabetic Ketoacidosis in a Patient with Cocaine Intoxication.Case reports in critical care · 2016Article
- Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. Prompt identification of the causal association and initiation of appropriate therapy should be instituted for this life threatening condition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.